肺線維症に対する新興治療薬としてのアルカロイド:分類,メカニズム,およびトランスレーションの可能性
Yafang Wang1, Chunlei Hua2, Henghui Zhang3
1Department of Rheumatology and Immunology, Inner Mongolia Autonomous Region People's Hospital, Hohhot, China.
Chemistry & biodiversity
|August 20, 2025
まとめ
自然のアルカロイドは,複数の経路をターゲットにすることで,肺線維症 (PF) の治療に希望を示しています. このレビューは,PFの予防と治療のための抗炎症性,抗酸化性,抗アポプト性効果に関する研究をまとめています.
科学分野:
- 薬理学について
- 肺科
- 自然製品 化学
背景:
- 肺線維症 (PF) は進行する肺疾患で,治療の選択肢は限られている.
- 自然製品,特にアルカロイドは,PFの潜在的な治療薬として出現しています.
- アルカロイドはPF病理と闘うための多目的のアプローチを提供します.
研究 の 目的:
- 肺線維症の予防と治療におけるアルカロイドの作用メカニズムを体系的に検討する.
- アルカロイドベースのPF療法に関する現在の実験的および臨床的研究結果を統合する.
- 新しい PF 治療の開発の課題と将来の研究方向を特定する.
主な方法:
- アルカロイドと肺線維症に関する実験的および臨床研究の包括的な文献検索.
- PFモデルにおけるアルカロイドによるシグナル伝達経路の分析
- PFに関連するアルカロイドの抗炎症性,抗酸化性,抗アポプト性効果の評価
主要な成果:
- アルカロイドは細胞外マトリックス沈着を抑制する効果を示しています.
- アルベオラ上皮細胞を保護し,肺線維細胞の活性化と増殖を抑制する.
- 複数のシグナル伝達経路は,アルカロイドによって反PF効果を発揮します.
結論:
- アルカロイドは肺線維症の治療に有望な自然化合物のクラスです.
- 彼らの多標的メカニズムは 従来の治療法よりも利点があります
- これらの発見をPFの臨床応用に移すためには,さらなる研究が必要である.
関連する概念動画
Pulmonary Hypertension: Classification and Pathogenesis
285
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
285
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
256
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
256
Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Drugs Used in Lower Respiratory Disorders: Overview
578
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
578


